Phase 3 Advanced Non-Small Cell Lung Cancer Clinical Trials
11 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–11 of 11 trials
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled74 locationsNCT07185997
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 3
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Non-small Cell Lung CancerNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Revolution Medicines, Inc.590 enrolled143 locationsNCT06881784
Recruiting
Phase 3
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR
Allist Pharmaceuticals, Inc.300 enrolled2 locationsNCT06956001
Recruiting
Phase 3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Advanced Non-Small Cell Lung CancerMET Exon 14 Mutation
Intergroupe Francophone de Cancerologie Thoracique133 enrolled29 locationsNCT06908993
Recruiting
Phase 3
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Neoadjuvant TherapyImmunotherapyLocally Advanced Non-Small Cell Lung Cancer+1 more
Sun Yat-sen University497 enrolled1 locationNCT06734702
Recruiting
Phase 3
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University311 enrolled3 locationsNCT07052669
Recruiting
Phase 3
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD.420 enrolled1 locationNCT06980272
Recruiting
Phase 3
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Advanced Non-Small Cell Lung Cancer
Qianfoshan Hospital98 enrolled1 locationNCT06043973